METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. It uses a special imaging agent to find cancer cells and a radioactive drug to destroy them. The goal is to see if the treatment is safe and shrinks tumors. About 49 …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for advanced prostate cancer: combination therapy enters human trials
Disease control Not yet recruitingThis early-stage trial tests the safety of combining a targeted radiation drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer. Participants receive either the radiation drug alone or both drugs together. The go…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a memory drug fight prostate cancer? small trial aims to find out
Disease control Not yet recruitingThis phase 2 trial tests whether memantine hydrochloride, a drug used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard hormone therapy. Fifteen men with metastatic castration-resistant prostate cancer will take memantine alongside…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Bin Xu • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Real-World study eyes drug combo for tough prostate cancer
Knowledge-focused Not yet recruitingThis study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC